We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Merck’s Melanoma Drug Shows Overall Survival Rate of 69%

News   Jun 04, 2014

 
Merck’s Melanoma Drug Shows Overall Survival Rate of 69%
 
 
Advertisement
 

RELATED ARTICLES

Drug Shown To Modulate the Inflammatory Response in Severe COVID-19

News

Scientists have identified a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

READ MORE

Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer

News

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to trial results.

READ MORE

Stroke Patients With COVID-19 Show Increased Inflammation and Stroke Severity

News

Stroke patients who also have COVID-19 showed increased systemic inflammation, a more serious stroke severity and a much higher rate of death, compared to stroke patients who did not have COVID-19, according to a new study.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE